西藏诺迪康药业股份有限公司关于持股5%以上股东股份质押展期的详细解读

要点摘要

• 西藏华西药业集团有限公司（简称“华西药业”）持有西藏诺迪康药业股份有限公司（简称“公司”）5,614.83万股股份，占公司总股本的17.42%，为第二大股东。
• 本次公告主要涉及华西药业对所持有的1,876万股公司股份进行质押展期，占其持股的33.41%，占公司总股本的5.82%。
• 质押展期后，并未新增质押或融资，仅为已有质押的延期。
• 质押展期手续已于2026年4月16日完成，现质押到期日为2027年4月16日，质权人为中信证券股份有限公司。
• 华西药业此次股份质押的用途为其自身生产经营，不涉及重大资产重组或业绩补偿等事项的担保或其他保障用途。
• 华西药业当前生产经营正常，具备履约能力。
• 截至公告日，华西药业累计被质押股份为1,876万股，无限售、无冻结，其余股份也均未有限售或冻结情况。

对投资者和股东的重要影响及潜在价格敏感信息

• 股东质押比例较高： 华西药业已将其所持公司股份的33.41%用于质押，虽然本次仅为展期，不涉及新增质押，但高比例质押本身依然是投资者需要关注的风险因素。
• 质押用途及履约能力： 公告明确本次质押仅用于华西药业自身的生产经营，并非用于资本运作或其他重大事项，短期内不太可能对公司经营产生负面影响。同时，公告强调华西药业具备履约能力，经营正常，这对稳定市场信心具有正面作用。
• 不涉及新增融资和风险敞口： 本次仅是对原有质押股份的展期，未引入新的质押或融资需求，意味着质押风险未进一步扩大。
• 对公司控制权及流通性的影响有限： 持续大比例质押若未来出现质押平仓风险，仍可能影响公司股价和控制权结构，投资者需持续关注后续质押股份的变化。

详细内容和背景

2026年4月16日，公司收到华西药业通知，华西药业已对所持有的1,876万股公司股份办理了质押展期业务，所有相关手续均已顺利完成。展期后，质押到期日从2026年4月16日顺延至2027年4月16日，质权人为中信证券股份有限公司。质押股份全部为无限售流通股，不涉及补充质押，也未发生股份冻结等情形。
公告同时披露，截至目前，华西药业持有公司5,614.83万股股份，占公司总股本的17.42%。本次质押展期之后，累计质押股份为1,876万股，占其持股比例的33.41%，占公司总股本的5.82%。其余股份未有质押、限售或冻结情况。

华西药业表示，此次质押行为完全基于自身生产经营需要，不涉及重大资产重组、业绩补偿等事项的担保或其他保障用途。公司经营正常，具备履约能力，不会对公司日常运营产生负面影响。
此外，本次股份质押展期不涉及新增融资，仅为对前期质押股份的续期安排。投资者应注意，虽然质押比例较高，但短期内公司经营及股东权益未受直接影响，需密切关注后续质押变化动态。

结论

本次股份质押展期可能对市场信心及公司股价产生一定影响，主要体现在高质押比例的持续与大股东流动性安排。当前未见新增风险，但投资者应持续关注质押比例的动态变化及公司后续公告。

免责声明

本文内容仅供投资参考，不构成任何投资建议。股市有风险，投资需谨慎。请投资者根据自身实际情况和专业咨询作出投资决策。

English Version

Detailed Analysis: Tibet Rhodiola Pharmaceutical Holdings – Share Pledge Extension by Major Shareholder Huaxi Pharma

Key Highlights

• Huaxi Pharmaceutical Group Co., Ltd. (“Huaxi Pharma”) holds 56.1483 million shares of Tibet Rhodiola Pharmaceutical Holdings (“the Company”), representing 17.42% of total share capital, making it the second-largest shareholder.
• This announcement concerns the extension of the share pledge on 18.76 million shares (33.41% of Huaxi Pharma’s holdings, 5.82% of total share capital).
• The extension does not involve new pledges or additional financing, but is a renewal of the existing pledge.
• The extension process was completed on April 16, 2026; the new maturity date is April 16, 2027. The pledgee is CITIC Securities Co., Ltd.
• The purpose of the pledge is for Huaxi Pharma’s own operating needs, not for M&A, performance guarantees, or other major asset transactions.
• Huaxi Pharma’s operations remain normal and it is considered capable of fulfilling its obligations.
• As of this announcement, all pledged shares are unrestricted and unfrozen. No other shares are under restriction or freezing.

Key Investor Insights and Potentially Price-Sensitive Information

• High Pledge Ratio: Huaxi Pharma has pledged 33.41% of its holdings. While this extension does not increase the pledged amount, the high ratio is a risk factor for investors to monitor.
• Pledge for Business Operations: The company clarifies the pledge is strictly for operating needs, not for capital transactions or asset restructuring, which should limit negative implications for daily operations or corporate governance in the short term.
• No Increase in Financing Risk: The extension does not introduce new financing or exposure, so the risk profile remains stable for now.
• Limited Near-term Impact on Control or Liquidity: Any forced sale risk due to high pledge levels could affect share price or control structure in the future. Investors should track future changes in the pledge ratio or new developments.

Detailed Background

On April 16, 2026, Huaxi Pharma notified the Company that it had completed the share pledge extension on 18.76 million shares. The new pledge expiry is April 16, 2027, with CITIC Securities as the pledgee. All pledged shares are freely tradable, not subject to lock-up or freeze, and no additional collateral was provided.
After the extension, Huaxi Pharma still holds 56.1483 million shares (17.42% of total share capital), with 18.76 million shares (33.41% of its holdings, 5.82% of total capital) pledged. There are no restrictions or freezes on the remaining shares.

According to Huaxi Pharma, the pledge is strictly for its own business needs and not related to asset transactions or performance guarantees. Operations are currently stable and no direct negative impact on the company’s day-to-day business is anticipated.
No new financing is involved; this is an extension of existing collateral arrangements. Investors should note the high pledge ratio but also that the company’s operations and shareholder interests have not been directly affected at this time. Ongoing monitoring of the pledge situation is advised.

Conclusion

This pledge extension may influence market confidence and share price due to the continued high pledge ratio and the major shareholder’s liquidity management. While no new risks have arisen, investors should closely monitor future changes in the pledge ratio and related disclosures.

Disclaimer

This article is for reference only and does not constitute investment advice. The stock market carries risks; investors should make decisions based on their own judgment and seek professional advice as needed.

View 西藏药业 Historical chart here